How do you lower an ApoB level that is too high?
An ApoB level that is too high is very treatable, and several proven agents are available. Statins are the first choice; PCSK9 inhibitors offer the strongest reduction when statins are insufficient or not tolerated.
Statins are the starting point when ApoB is too high. They powerfully lower both LDL cholesterol and ApoB, and are recommended for virtually everyone with an elevated cardiovascular risk. If the effect is insufficient, ezetimibe is the next step: it inhibits cholesterol absorption in the intestine and provides an additional reduction in ApoB.
People who cannot tolerate statins, or whose values are far too high, have more options. PCSK9 inhibitors (the injectable drugs alirocumab and evolocumab) lower ApoB more powerfully than any other available agent. Inclisiran works through the same mechanism but needs to be administered only twice a year, which makes adherence easier. It still has to prove its effect on hard cardiovascular outcomes in large trials. Bempedoic acid is a tablet option for those who cannot tolerate statins: it lowers LDL and ApoB via a slightly different step in cholesterol metabolism.
For the most severe hereditary forms of high cholesterol, where the agents mentioned above are insufficient, two further options exist. Evinacumab (an ANGPTL3 inhibitor) lowers ApoB powerfully without the serious side effects of the older drug mipomersen. Mipomersen targets ApoB-100 directly, but carries substantial side effects and is used only in exceptional circumstances.
Lifestyle matters, but less than you might hope. Consuming roughly 3.5 grams of oat beta-glucan daily (such as that found in oat bran) lowers ApoB by an average of 0.03 g/l -- a modest but measurable effect. Exercise and healthier eating improve lipoprotein metabolism, particularly in people with abdominal fat and insulin resistance. Yet one study of people who had undergone bypass surgery and were already using statins found that an intensive year of exercise and dieting did not produce a significant reduction in ApoB. Lifestyle is valuable, but can rarely replace medication when ApoB is clearly elevated.
Finally: ApoB measures the total number of harmful lipid particles in the blood and gives a more accurate picture of cardiac risk than LDL cholesterol alone. This holds true both before you start treatment and while you are already taking medication. It is therefore sensible to monitor ApoB during treatment as a measure of how much progress has been made.
The medication recommendations rest on multiple reviews and are based on large clinical trials with hard endpoints (heart attacks, mortality). The oat bran finding comes from a summary of 58 randomised trials. The lifestyle data in patients after bypass surgery and in people with metabolic syndrome is more limited and is based on small or non-randomised studies, so the researchers themselves do not draw cause-and-effect conclusions. For inclisiran, bempedoic acid and evinacumab, evidence of LDL/ApoB lowering is available, but large trials also measuring heart attacks and mortality as endpoints are still ongoing or exist for only some of these agents.
What is a healthy ApoB level?
There is no fixed 'healthy' ApoB value, but below 82 mg/dL the risk of a stroke already decreases measurably. ApoB offers better protection than LDL alone, but discuss your personal target with your doctor, as it depends on your overall risk profile and any medication you may be taking.
Who should have their ApoB measured?
Measuring ApoB is worthwhile for more people than current guidelines suggest: not only in cases of elevated blood fats, but also with excess weight, diabetes, familial hypercholesterolaemia, women after menopause, and people already taking cholesterol-lowering medication.
What does your ApoB value tell you about your risk of cardiovascular disease?
ApoB gives a more accurate picture of your cardiovascular disease risk than standard LDL cholesterol. Ask your doctor to also measure ApoB (and possibly Lp(a)), especially if you have doubts about your risk profile.
Is ApoB more important than regular cholesterol (LDL)?
ApoB consistently predicts cardiovascular disease better than LDL cholesterol. If you want to know how high your risk truly is, ask your doctor to measure ApoB alongside the standard cholesterol panel.
How early in life should you start lowering your LDL cholesterol to prevent cardiovascular disease?
Starting as early as possible pays off: LDL damage accumulates from childhood, and every year that your LDL remains lower counts. If familial high cholesterol runs in your family, discuss with your doctor whether screening from a young age makes sense.
What does a low-carbohydrate diet do to your LDL cholesterol in the long term?
A low-carbohydrate diet raises LDL in the short term, but that effect often disappears after a year; the effect on triglycerides and HDL is more favourable, but what this means for your long-term heart disease risk has not yet been proven.